Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium.
BACKGROUND Real-world data on efficacy and safety of tarlatamab in small cell lung cancer (SCLC) remains limited. METHODS This retrospective study analyzed 265 tarlatamab-treated patients across 11 U.S. centers in the ONWARD-SCLC consortium (11/2023-4/2025), evaluating clinical outcomes, CRS, ICANS, and impact of pro...